The Indian Journal of Pediatrics

, Volume 84, Issue 6, pp 425–429

Efficacy and Safety of 2% Topical Propranolol Cream for the Treatment of Proliferating Infantile Strawberry Hemangiomas

  • Yuanyuan Wang
  • Xingcun Zhang
  • Yadong Yang
  • Junbo Zhang
  • Yunchuan Yang
  • Yuangang Lu
Original Article
  • 109 Downloads

Abstract

Objective

To evaluate the efficacy and safety of 2% topical propranolol cream in the treatment of proliferating infantile strawberry hemangiomas.

Methods

A total of 40 infants were enrolled; 2% propranolol cream was applied three times daily. In the subsequent monthly visit, dynamic changes in tumor size, texture, and color were recorded. The adverse events (AEs) were observed. Treatment outcomes were scored on a four-point scale. All patients were followed up for 12 mo after treatment.

Results

The overall response was graded Scale 1 (poor response) in 2 patients, Scale 2 (moderate response) in 15 patients, Scale 3 (good response) in 17 patients, and Scale 4 (excellent response) in 6 patients. No significant differences were seen in treatment outcomes between female and male patients, among lesion locations/size, or in the age at the start of the treatment. No obvious AEs were reported.

Conclusions

2% topical propranolol cream is safe and effective for the treatment of proliferating infantile strawberry hemangiomas.

Keywords

Topical propranolol Infant Strawberry hemangiomas Safety Efficacy β-adrenergic receptor blocker 

Supplementary material

12098_2017_2303_MOESM1_ESM.docx (128 kb)
ESM 1(DOCX 128 kb)

References

  1. 1.
    Schwartz RA, Sidor MI, Musumeci ML, Lin RL, Micali G. Infantile haemangiomas: a challenge in paediatric dermatology. J Eur Acad Dermatol Venereol. 2010;24:631–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Smith Jr SP, Buckingham ED, Williams EF 3rd. Management of cutaneous juvenile hemangiomas. Facial Plast Surg. 2008;24:50–64.CrossRefPubMedGoogle Scholar
  3. 3.
    Oksiuta M, Matuszczak E, Debek W, Dzienis-Koronkiewicz E, Hermanowicz A. Treatment of rapidly proliferating haemangiomas in newborns with propranolol and review of the literature. J Matern Fetal Neonatal Med. 2016;29:64–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Tan CE, Itinteang T, Leadbitter P, Marsh R, Tan ST. Low-dose propranolol regimen for infantile haemangioma. J Paediatr Child Health. 2015;51:419–24.PubMedGoogle Scholar
  5. 5.
    Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Pediatr Dermatol. 2011;28:169–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2011;64:445–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006;118:882–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg. 1997;99:1301–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Greenberger S, Bischoff J. Pathogenesis of infantile haemangioma. Br J Dermatol. 2013;169:12–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162:466–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Leaute-Labreze C. Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.Google Scholar
  12. 12.
    Chen TS, Eichenfield LF, Friedlander SF. Infantile hemangiomas: an update on pathogenesis and therapy. Pediatrics. 2013;131:99–108.CrossRefPubMedGoogle Scholar
  13. 13.
    Mazereeuw-Hautier J, Hoeger PH, Benlahrech S, et al. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J Pediatr. 2010;157:340–2.CrossRefPubMedGoogle Scholar
  14. 14.
    Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr. 2011;170:493–501.CrossRefPubMedGoogle Scholar
  15. 15.
    Buckmiller LM. Propranolol treatment for infantile hemangiomas. Curr Opin Otolaryngol Head Neck Surg. 2009;17:458–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Ji Y, Chen S, Xu C, Li L, Xiang B. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action. Br J Dermatol. 2015;172:24–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Jian D, Chen X, Babajee K, et al. Adverse effects of propranolol treatment for infantile hemangiomas in China. J Dermatolog Treat. 2014;25:388–90.CrossRefPubMedGoogle Scholar
  18. 18.
    Kunzi-Rapp K. Topical propranolol therapy for infantile hemangiomas. Pediatr Dermatol. 2012;29:154–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Bonifazi E, Colonna V, Mazzotta F, Balducci G, Laforgia N. Propranolol in rapidly growing hemangiomas. Eur J Pediatr Dermatol. 2008;18:185–92.Google Scholar
  20. 20.
    Xu G, Lv R, Zhao Z, Huo R. Topical propranolol for treatment of superficial infantile hemangiomas. J Am Acad Dermatol. 2012;67:1210–3.CrossRefPubMedGoogle Scholar
  21. 21.
    Zaher H, Rasheed H, Esmat S, et al. Propranolol and infantile hemangiomas: different routes of administration, a randomized clinical trial. Eur J Dermatol. 2013;23:646–52.PubMedGoogle Scholar
  22. 22.
    Kovacevic M, Lukinovic Skudar V, Maricic G, Krnjevic-Pezic G, Stanimirovic A. Topical propranolol cream in treatment of superficial infantile hemangiomas: a literature review and 4 years of clinical experience. Acta Dermatovenerol APA. 2014;23:75–8.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2017

Authors and Affiliations

  • Yuanyuan Wang
    • 1
  • Xingcun Zhang
    • 1
  • Yadong Yang
    • 1
  • Junbo Zhang
    • 1
  • Yunchuan Yang
    • 1
  • Yuangang Lu
    • 1
  1. 1.Department of Plastic and Cosmetic Surgery, Daping Hospital & Institute of Surgery ResearchThird Military Medical UniversityChongqingPeople’s Republic of China

Personalised recommendations